Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
- 1 December 1999
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 354 (9194), 1932-1939
- https://doi.org/10.1016/s0140-6736(99)05246-0
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- DOES EXPOSURE TO IMMUNOSUPPRESSIVE THERAPY INCREASE THE 10 YEAR MALIGNANCY AND MORTALITY RISKS IN RHEUMATOID ARTHRITIS? A MATCHED COHORT STUDYRheumatology, 1996
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- Lymphoma and Luekemia in Rheumatoid ArthritisJCR: Journal of Clinical Rheumatology, 1996
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid DiseaseImmunological Reviews, 1995
- THE THERAPEUTIC EFFECTS OF AN ENGINEERED HUMAN ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY (CDP571) IN RHEUMATOID ARTHRITISRheumatology, 1995
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- The american college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritisArthritis & Rheumatism, 1992